AngioDynamics, Inc. (NASDAQ:ANGO) Stock Has Average Target Price of $19.00

Shares of AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) have received a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $19.00.

Several research analysts have issued reports on ANGO shares. Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. HC Wainwright reduced their target price on AngioDynamics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Thursday, October 15th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of AngioDynamics in a research report on Friday, October 9th.

View Our Latest Analysis on ANGO

AngioDynamics Stock Performance

Shares of AngioDynamics stock opened at $11.87 on Monday. The firm’s 50 day moving average is $13.42 and its 200 day moving average is $12.54. The firm has a market capitalization of $499.13 million, a PE ratio of -15.22 and a beta of 0.30. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last released its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics had a negative return on equity of 4.49% and a negative net margin of 10.12%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts anticipate that AngioDynamics will post -0.27 earnings per share for the current year.

Insider Buying and Selling

In other AngioDynamics news, CFO Stephen Trowbridge sold 23,615 shares of the stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $12.27, for a total transaction of $289,756.05. Following the completion of the transaction, the chief financial officer directly owned 280,461 shares of the company’s stock, valued at approximately $3,441,256.47. This represents a 7.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in AngioDynamics during the 2nd quarter valued at about $49,480,000. Weber Capital Management LLC ADV bought a new position in AngioDynamics in the second quarter valued at $17,649,392. Bastion Asset Management Inc. increased its position in shares of AngioDynamics by 17.4% during the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after purchasing an additional 194,822 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of AngioDynamics by 3.5% during the first quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after acquiring an additional 32,476 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in AngioDynamics by 0.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after purchasing an additional 5,509 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc. develops, manufactures and markets medical devices used in minimally invasive procedures. Its products are designed for clinicians in areas including vascular access, peripheral vascular disease and oncology. The company’s offerings include vascular access devices such as ports and catheters, as well as technologies used in vascular intervention and cancer treatment. These include the Auryon atherectomy system, which is used to treat certain peripheral arterial conditions, and the NanoKnife System, which uses irreversible electroporation in tumor ablation procedures.

Further Reading

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.